Abstract: The present invention relates to a (bio)pharmaceutical composition, particularly a liquid (e.g. aqueous) biopharmaceutical composition, more particularly a liquid biopharmaceutical composition comprising an anti-EGFR/anti-LGR5 bispecific antibody. The present invention also relates inter alia to a method of manufacturing the composition, to a kit including the composition, to a package including the composition, to a method of manufacturing the package, and to methods of treatment using the composition and/or package, especially cancer treatments, for example, for the treatment of colorectal cancer.

Abstract: A laser beam (4) is guided onto or through a sample (1) which while exposed to the laser is scanned by means of a digital scanner (2). The apparatus for performing this method comprises a laser light source (3) and a digital scanner (2).

Abstract: The present invention is directed to stable protein formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing therapeutic proteins in aqueous solution.

Abstract: The present invention provides stable liquid formulations of antibodies suitable for parenteral administration. Also, provided are aqueous solutions which have high concentrations of therapeutical antibodies which may be used to produce therapeutical liquid formulations. The present invention also relates to uses, such as medical uses, of the stable liquid formulations and processes for the production of the stable liquid formulations.

Abstract: A laser beam (4) is guided onto or through a sample (1) which while exposed to the laser is scanned by means of a digital scanner (2). The apparatus for performing this method comprises a laser light source (3) and a digital scanner (2).

Abstract: For detecting and storing information on optical properties analytical samples are digitally scanned with filters put in front of and behind the samples. A device for performing this method has means for putting filters on each side of the analytical samples. The filters may be polarizers, fluorescence filters etc.

Abstract: The invention relates to a liquid formulation comprising a growth hormone or a substance, which stimulates release or potentiates the activity of endogenous hGH; a polyethylene-polypropylene glycol; a citrate/phosphate buffer, an alkali metal salt and an alkaline earth metal salt or a pseudo alkaline earth metal salt, and to a process of preparation thereof.

Abstract: The invention relates to a liquid formulation comprising a growth hormone or a substance, which stimulates release or potentiates the activity of endogenous hGH; a polyethylene-polypropylene glycol; a citrate/phosphate buffer, an alkali metal salt and an alkaline earth metal salt or a pseudo alkaline earth metal salt, and to a process of preparation thereof.

Abstract: The present invention provides stable liquid formulations of antibodies suitable for parenteral administration. Also, provided are aqueous solutions which have high concentrations of therapeutical antibodies which may be used to produce therapeutical liquid formulations. The present invention also relates to uses, such as medical uses, of the stable liquid formulations and processes for the production of the stable liquid formulations.

Abstract: The present invention provides stable liquid formulations of antibodies suitable for parenteral administration. Also provided are aqueous solutions which have high concentrations of therapeutical antibodies which may be used to produce therapeutical liquid formulations. The present invention also relates to uses, such as medical uses, of the stable liquid formulations and processes for the production of the stable liquid formulations.

Abstract: This invention provides pharmaceutical compositions comprising TGF-&bgr;.

Abstract: The present invention provides a freeze dried pharmaceutical composition comprising hirudin, potassium phosphate and a sugar.

Abstract: This invention provides pharmaceutical compositions comprising TGF-&bgr;.

Abstract: The invention concerns TGF-&bgr; in a crystalline form which shows no adsorption or less adsorption to the walls of vials than the soluted TGF-&bgr; and which is more stable towards oxidative agents than the soluted form. TGF-&bgr; crystals of the invention can be used for structure determination and for drug design and for the production of a slow release pharmaceutical preparation.

Abstract: The present invention provides a freeze dried pharmaceutical composition comprising hirudin and a water-soluble salt of calcium and/or magnesium.

Abstract: The invention provides fibrillated calcitonin for use in treating calcium deficiency diseases.

Abstract: A stable aqueous solution of human calcitonin (hCT) which remains free of hCT fibrils for at least 24 hours at 25.degree. C. which comprises water, hCT and a cellulose derivative and/or an acid, the type of acid and the amount of acid being so chosen as to achieve said stability in the absence of a salt or a buffer.

Abstract: The present invention relates to aqueous depot formulations of hirudin, particularly desulphatohirudin, which are very stable. These formulations contain water, hirudin, and calcium, magnesium, or zinc ions in the form of water insoluble salts, the salts being in a concentration of from 100 mM to 600 mM.